Loading stock data…
Allogene Therapeutics, Inc. (ALLO)
$2.13+0.07 (+3.40%)
Market ClosedLast close Jun 26
Allogene Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Allogene Therapeutics, Inc. in the Healthcare sector is trading at $2.13 with a market capitalization of $749M. Wall Street consensus targets $8.48 (10 analysts), implying a +298.4% move over the next 12 months. The stock is currently 52% below its 52-week high of $4.46, remaining 19.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +298.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$46.09M↓ | -$42.40M↑ | -$44.90M↑ | -$54.44M↑ | -$65.19M |
| Net Income | -$42.61M↓ | -$38.81M↑ | -$41.40M↑ | -$50.94M↑ | -$59.73M |
Peer Comparison
JNJUNHPFE
Fundamentals
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CA...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$748.99M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.46
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-62.31%
Volume
Today's trading volume
25.92M
Recent News
Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions
Allogene Therapeutics is back in focus as its fair value estimate has been reset to US$8.49 from US$7.47, alongside a mix of price target moves across the Street. Some analysts have raised targets by US$2 to US$4 after the ALPHA3 trial update and refreshed models, while others have trimmed targets by around US$1 as they weigh execution risk and funding needs. Read on to see how to track these shifting views and what signals to watch as the Allogene Therapeutics story continues to...
How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the small-cap stocks with potential to rise 1000 percent. The company’s 2026 setup now rests on whether it can turn its off-the-shelf CAR T platform into clinical evidence across both cancer and autoimmune disease. In its May 13 first-quarter update, Allogene said its pivotal Phase 2 ALPHA3 trial […]
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases
By Karen Roman Imviva Biotech said the FDA cleared its Investigational New Drug application for CTA313, a dual-targeted CAR-T therapy for the treatment of B-cell-mediated autoimmune diseases. Phase 1b of this clinical trial will study CTA313 in patients with systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitis, among other autoimmune conditions, the company stated. […] The post FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases appeared first on Ex
Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the top penny stocks to buy in investors’ stock portfolio. On May 13, Allogene Therapeutics, Inc. (NASDAQ:ALLO) reiterated positive interim results in the ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel), its investigational, allogeneic CAR T-cell therapy targeting CD19. In ongoing trials, Cema-cel was well tolerated, with no treatment-related serious […]